Interstitial lung disease
RecruitingEfficacy and Safety of BI 1015550 in Adults with Fibrosing Interstitial Lung Disease at Risk of Disease Progression: A Randomized, Placebo‑Controlled Trial
Efficacy and Safety of BI 1015550 in Adults with Fibrosing Interstitial Lung Disease at Risk of Disease Progression: A Randomized, Placebo‑Controlled Trial
- Disease:Interstitial lung disease
- Substances:Nerandomilast
France- Participants:18–64 years · 65+ years
- Substances:Nerandomilast
- Sponsor:Boehringer Ingelheim Espana S.A.













